Insights into Newer Antimicrobial Agents Against Gram-negative Bacteria

Overview

Journal Microbiol Insights

Publisher Sage Publications

Specialty Biology

Date 2016 Mar 26

PMID 27013887

Citations 27

Authors

Neelam Taneja

Harsimran Kaur

Affiliations

Soon will be listed here.

Abstract

Currently, drug resistance, especially against cephalosporins and carbapenems, among gram-negative bacteria is an important challenge, which is further enhanced by the limited availability of drugs against these bugs. There are certain antibiotics (colistin, fosfomycin, temocillin, and rifampicin) that have been revived from the past to tackle the menace of superbugs, including members of Enterobacteriaceae, Acinetobacter species, and Pseudomonas species. Very few newer antibiotics have been added to the pool of existing drugs. There are still many antibiotics that are passing through various phases of clinical trials. The initiative of Infectious Disease Society of America to develop 10 novel antibiotics against gram-negative bacilli by 2020 is a step to fill the gap of limited availability of drugs. This review aims to provide insights into the current and newer drugs in pipeline for the treatment of gram-negative bacteria and also discusses the major challenging issues for their management.

Citing Articles

Enhancing antibiotic therapy through comprehensive pharmacokinetic/pharmacodynamic principles.

Alikhani M, Nazari M, Hatamkhani S Front Cell Infect Microbiol. 2025; 15:1521091.

PMID: 40070375 PMC: 11893874. DOI: 10.3389/fcimb.2025.1521091.

Unraveling bacterial stress responses: implications for next-generation antimicrobial solutions.

Avci F World J Microbiol Biotechnol. 2024; 40(9):285.

PMID: 39073503 PMC: 11286680. DOI: 10.1007/s11274-024-04090-z.

Emergence of NDM-1-producing from reservoir water in Northeast Thailand.

Karnmongkol C, Wiriyaampaiwong P, Teerakul M, Treeinthong J, Srisamoot N, Tankrathok A Vet World. 2023; 16(11):2321-2328.

PMID: 38152267 PMC: 10750751. DOI: 10.14202/vetworld.2023.2321-2328.

Bloodstream Infections Caused by Multidrug Resistant Bacteria: Clinical and Microbiological Features and Mortality.

Kalayci Cekin Z, Oncul A, Bayraktar B Sisli Etfal Hastan Tıp Bul. 2023; 57(3):416-425.

PMID: 37900327 PMC: 10600613. DOI: 10.14744/SEMB.2023.31697.

Zinc chloride is effective as an antibiotic in biofilm prevention following septoplasty.

Noach N, Lavy E, Reifen R, Friedman M, Kirmayer D, Zelinger E Sci Rep. 2023; 13(1):8344.

PMID: 37221180 PMC: 10206080. DOI: 10.1038/s41598-023-35069-9.

References

Maseda E, Aguilar L, Gimenez M, Gilsanz F . Ceftolozane/tazobactam (CXA 201) for the treatment of intra-abdominal infections. Expert Rev Anti Infect Ther. 2014; 12(11):1311-24. DOI: 10.1586/14787210.2014.950230. View

Zhanel G, Lawson C, Adam H, Schweizer F, Zelenitsky S, Lagace-Wiens P . Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs. 2013; 73(2):159-77. DOI: 10.1007/s40265-013-0013-7. View

Viertel T, Ritter K, Horz H . Viruses versus bacteria-novel approaches to phage therapy as a tool against multidrug-resistant pathogens. J Antimicrob Chemother. 2014; 69(9):2326-36. DOI: 10.1093/jac/dku173. View

Zavascki A, Bulitta J, Landersdorfer C . Combination therapy for carbapenem-resistant Gram-negative bacteria. Expert Rev Anti Infect Ther. 2013; 11(12):1333-53. DOI: 10.1586/14787210.2013.845523. View

Raz R . Fosfomycin: an old--new antibiotic. Clin Microbiol Infect. 2011; 18(1):4-7. DOI: 10.1111/j.1469-0691.2011.03636.x. View

Yau W, Owen R, Poudyal A, Bell J, Turnidge J, Yu H . Colistin hetero-resistance in multidrug-resistant Acinetobacter baumannii clinical isolates from the Western Pacific region in the SENTRY antimicrobial surveillance programme. J Infect. 2008; 58(2):138-44. DOI: 10.1016/j.jinf.2008.11.002. View

Sabouri Ghannad M, Mohammadi A . Bacteriophage: time to re-evaluate the potential of phage therapy as a promising agent to control multidrug-resistant bacteria. Iran J Basic Med Sci. 2013; 15(2):693-701. PMC: 3586887. View

Macone A, Caruso B, Leahy R, Donatelli J, Weir S, Draper M . In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. Antimicrob Agents Chemother. 2013; 58(2):1127-35. PMC: 3910882. DOI: 10.1128/AAC.01242-13. View

Araj G, Jaber F . In vitro activity of fosfomycin and other antimicrobials against uropathogenic Escherichia coli and Klebsiella pneumoniae at a tertiary care center in Lebanon. J Med Liban. 2012; 60(3):142-7. View

10.

Endimiani A, Patel G, Hujer K, Swaminathan M, Perez F, Rice L . In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin. Antimicrob Agents Chemother. 2009; 54(1):526-9. PMC: 2798518. DOI: 10.1128/AAC.01235-09. View

11.

Tascini C, Tagliaferri E, Giani T, Leonildi A, Flammini S, Casini B . Synergistic activity of colistin plus rifampin against colistin-resistant KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2013; 57(8):3990-3. PMC: 3719736. DOI: 10.1128/AAC.00179-13. View

12.

Garonzik S, Li J, Thamlikitkul V, Paterson D, Shoham S, Jacob J . Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother. 2011; 55(7):3284-94. PMC: 3122440. DOI: 10.1128/AAC.01733-10. View

13.

Popovic M, Steinort D, Pillai S, Joukhadar C . Fosfomycin: an old, new friend?. Eur J Clin Microbiol Infect Dis. 2009; 29(2):127-42. DOI: 10.1007/s10096-009-0833-2. View

14.

Giamarellou H, Galani L, Baziaka F, Karaiskos I . Effectiveness of a double-carbapenem regimen for infections in humans due to carbapenemase-producing pandrug-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother. 2013; 57(5):2388-90. PMC: 3632902. DOI: 10.1128/AAC.02399-12. View

15.

Lee G, Burgess D . Polymyxins and Doripenem Combination Against KPC-Producing Klebsiella pneumoniae. J Clin Med Res. 2013; 5(2):97-100. PMC: 3601507. DOI: 10.4021/jocmr1220w. View

16.

Hanberger H, Giske C, Giamarellou H . When and how to cover for resistant gram-negative bacilli in severe sepsis and septic shock. Curr Infect Dis Rep. 2011; 13(5):416-25. DOI: 10.1007/s11908-011-0200-1. View

17.

Xie J, Wang T, Sun J, Chen S, Cai J, Zhang W . Optimal tigecycline dosage regimen is urgently needed: results from a pharmacokinetic/pharmacodynamic analysis of tigecycline by Monte Carlo simulation. Int J Infect Dis. 2013; 18:62-7. DOI: 10.1016/j.ijid.2013.09.008. View

18.

Woodford N, Pike R, Meunier D, Loy R, Hill R, Hopkins K . In vitro activity of temocillin against multidrug-resistant clinical isolates of Escherichia coli, Klebsiella spp. and Enterobacter spp., and evaluation of high-level temocillin resistance as a diagnostic marker for OXA-48 carbapenemase. J Antimicrob Chemother. 2013; 69(2):564-7. DOI: 10.1093/jac/dkt383. View

19.

Bergen P, Tsuji B, Bulitta J, Forrest A, Jacob J, Sidjabat H . Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother. 2011; 55(12):5685-95. PMC: 3232764. DOI: 10.1128/AAC.05298-11. View

20.

Sutcliffe J, OBrien W, Fyfe C, Grossman T . Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother. 2013; 57(11):5548-58. PMC: 3811277. DOI: 10.1128/AAC.01288-13. View